Leerink Partners analyst Jonathan Chang has reiterated their neutral stance on KPTI stock, giving a Hold rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jonathan Chang’s rating is based on a combination of factors, including Karyopharm Therapeutics’ recent financial performance and future prospects. The company’s reported revenue for Xpovio slightly exceeded expectations for the second quarter of 2025, but the full-year revenue guidance was lowered, indicating potential challenges in sustaining growth.
Additionally, the timeline for key clinical trials has been extended, with significant data readouts now expected later than initially planned. This delay in clinical milestones, coupled with the company’s constrained cash position, suggests uncertainty in achieving long-term growth. As a result, Jonathan Chang remains cautious, opting for a Hold rating while awaiting clearer evidence of sustainable growth and successful execution of clinical programs.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $4.00 price target.